TWI739783B - 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物 - Google Patents
作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物 Download PDFInfo
- Publication number
- TWI739783B TWI739783B TW105143703A TW105143703A TWI739783B TW I739783 B TWI739783 B TW I739783B TW 105143703 A TW105143703 A TW 105143703A TW 105143703 A TW105143703 A TW 105143703A TW I739783 B TWI739783 B TW I739783B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- group
- het
- substituted
- heterocyclic group
- Prior art date
Links
- 0 *[C@@](CCO*)CC1(*)c2cc(-c3nc(*=*=I)ncc3*)cc(C#N)c2N(*)C1 Chemical compound *[C@@](CCO*)CC1(*)c2cc(-c3nc(*=*=I)ncc3*)cc(C#N)c2N(*)C1 0.000 description 7
- QQHCZIGCKZYIJK-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)(C)c1cc(-c2ccnc(Nc(cc(c(C(O)=O)c3)Cl)c3OC)n2)c2)c1c2C#N)=O Chemical compound CC(C)(C)OC(N(CC(C)(C)c1cc(-c2ccnc(Nc(cc(c(C(O)=O)c3)Cl)c3OC)n2)c2)c1c2C#N)=O QQHCZIGCKZYIJK-UHFFFAOYSA-N 0.000 description 1
- SLTBEMKENUGZDJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1(C)C)c2c1cc(B1OC(C)(C)C(C)(C)O1)cc2C#N)=O Chemical compound CC(C)(C)OC(N(CC1(C)C)c2c1cc(B1OC(C)(C)C(C)(C)O1)cc2C#N)=O SLTBEMKENUGZDJ-UHFFFAOYSA-N 0.000 description 1
- ZMZLWAWOJPOEOI-JGCGQSQUSA-N CC(C)(C)[Si](C)(C)OC[C@]1(C)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(F)c4)c4OC4CC4)n3)cc(C#N)c2NC1 Chemical compound CC(C)(C)[Si](C)(C)OC[C@]1(C)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(F)c4)c4OC4CC4)n3)cc(C#N)c2NC1 ZMZLWAWOJPOEOI-JGCGQSQUSA-N 0.000 description 1
- SQDXMSPXVYLVFO-JGCGQSQUSA-N CC(C)(C)[Si](C)(C)OC[C@]1(C)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(OC4CC4)c4)c4F)n3)cc(C#N)c2NC1 Chemical compound CC(C)(C)[Si](C)(C)OC[C@]1(C)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(OC4CC4)c4)c4F)n3)cc(C#N)c2NC1 SQDXMSPXVYLVFO-JGCGQSQUSA-N 0.000 description 1
- BAIUUICQTSVWSL-UHFFFAOYSA-N CC(C)COC(OC(c1cc(NC(C)=O)c(C)cc1)=O)=O Chemical compound CC(C)COC(OC(c1cc(NC(C)=O)c(C)cc1)=O)=O BAIUUICQTSVWSL-UHFFFAOYSA-N 0.000 description 1
- BLDOZYVSDJRZKH-UHFFFAOYSA-N CC(C)N(CC1)CCN1C(Cc(ccc(Cl)c1)c1N)=O Chemical compound CC(C)N(CC1)CCN1C(Cc(ccc(Cl)c1)c1N)=O BLDOZYVSDJRZKH-UHFFFAOYSA-N 0.000 description 1
- ZHXITFMUFDDONY-UHFFFAOYSA-N CC1(CO)c2cc(-c3ccnc(Nc4c(C)ccc(C#N)c4)n3)cc(C#N)c2NC1 Chemical compound CC1(CO)c2cc(-c3ccnc(Nc4c(C)ccc(C#N)c4)n3)cc(C#N)c2NC1 ZHXITFMUFDDONY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- XNBLEAGPKPYTCT-UHFFFAOYSA-N CNC(c(ccc(F)c1)c1F)=O Chemical compound CNC(c(ccc(F)c1)c1F)=O XNBLEAGPKPYTCT-UHFFFAOYSA-N 0.000 description 1
- VCVQUCAIJKTZQU-UHFFFAOYSA-N COC(c(cc(c([N+]([O-])=O)c1)OC)c1Cl)=O Chemical compound COC(c(cc(c([N+]([O-])=O)c1)OC)c1Cl)=O VCVQUCAIJKTZQU-UHFFFAOYSA-N 0.000 description 1
- LUISPVNHVFUFES-UHFFFAOYSA-N COC(c(cc(cc1)[N+]([O-])=O)c1C1=CCOCC1)OC Chemical compound COC(c(cc(cc1)[N+]([O-])=O)c1C1=CCOCC1)OC LUISPVNHVFUFES-UHFFFAOYSA-N 0.000 description 1
- WVPMJFDSKVTEIQ-UHFFFAOYSA-N COc(c([N+]([O-])=O)c1)cc(CO)c1Cl Chemical compound COc(c([N+]([O-])=O)c1)cc(CO)c1Cl WVPMJFDSKVTEIQ-UHFFFAOYSA-N 0.000 description 1
- LEEIHBRGOFAAKY-UHFFFAOYSA-N COc(cc(cc1)C(NC2CCOCC2)=O)c1[N+]([O-])=O Chemical compound COc(cc(cc1)C(NC2CCOCC2)=O)c1[N+]([O-])=O LEEIHBRGOFAAKY-UHFFFAOYSA-N 0.000 description 1
- DRDOUUATQDCECH-UHFFFAOYSA-N CS(c(cc1)cc(C#CC2CC2)c1[N+]([O-])=O)(=O)=O Chemical compound CS(c(cc1)cc(C#CC2CC2)c1[N+]([O-])=O)(=O)=O DRDOUUATQDCECH-UHFFFAOYSA-N 0.000 description 1
- ZHXITFMUFDDONY-HSZRJFAPSA-N C[C@@]1(CO)c(cc(cc2C#N)-c3ccnc(Nc4cc(C#N)ccc4C)n3)c2NC1 Chemical compound C[C@@]1(CO)c(cc(cc2C#N)-c3ccnc(Nc4cc(C#N)ccc4C)n3)c2NC1 ZHXITFMUFDDONY-HSZRJFAPSA-N 0.000 description 1
- RUAYESDPZPQWKG-XMMPIXPASA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc(c(C)c4)cc(C(NC)=O)c4F)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc(c(C)c4)cc(C(NC)=O)c4F)n3)cc(C#N)c2NC1 RUAYESDPZPQWKG-XMMPIXPASA-N 0.000 description 1
- WPMMAADCSGORHR-AREMUKBSSA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(F)c4)c4OC4CC4)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc(C(NC)=O)c(F)c4)c4OC4CC4)n3)cc(C#N)c2NC1 WPMMAADCSGORHR-AREMUKBSSA-N 0.000 description 1
- IGIVJMJBNABMTD-HHHXNRCGSA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc4C(NCC5COC5)=O)c(C)cc4F)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc(cc4C(NCC5COC5)=O)c(C)cc4F)n3)cc(C#N)c2NC1 IGIVJMJBNABMTD-HHHXNRCGSA-N 0.000 description 1
- KTKIDNLSWOEHAZ-AREMUKBSSA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc4c(CCCCN)ccc(C#N)c4)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc4c(CCCCN)ccc(C#N)c4)n3)cc(C#N)c2NC1 KTKIDNLSWOEHAZ-AREMUKBSSA-N 0.000 description 1
- UHQFQXCDWMDXTR-XMMPIXPASA-N C[C@@]1(CO)c2cc(-c3ccnc(Nc4cc(C#N)cc(C(O)=O)c4C)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(CO)c2cc(-c3ccnc(Nc4cc(C#N)cc(C(O)=O)c4C)n3)cc(C#N)c2NC1 UHQFQXCDWMDXTR-XMMPIXPASA-N 0.000 description 1
- ZEJZWWAPHPFXAK-RUZDIDTESA-N C[C@@]1(COC(C)=O)c2cc(-c3ccnc(Nc4cc(C#N)ccc4C)n3)cc(C#N)c2NC1 Chemical compound C[C@@]1(COC(C)=O)c2cc(-c3ccnc(Nc4cc(C#N)ccc4C)n3)cc(C#N)c2NC1 ZEJZWWAPHPFXAK-RUZDIDTESA-N 0.000 description 1
- IQPLGOCGOCXUPI-UHFFFAOYSA-N Cc(c(C1=CCNCC1)c1)cc([N+]([O-])=O)c1OC Chemical compound Cc(c(C1=CCNCC1)c1)cc([N+]([O-])=O)c1OC IQPLGOCGOCXUPI-UHFFFAOYSA-N 0.000 description 1
- AXXXTPRFYAKSGZ-UHFFFAOYSA-N Cc(c([N+]([O-])=O)c1)cc(-c2c[n](C)nc2)c1C#N Chemical compound Cc(c([N+]([O-])=O)c1)cc(-c2c[n](C)nc2)c1C#N AXXXTPRFYAKSGZ-UHFFFAOYSA-N 0.000 description 1
- UBAWHHHAAFFKGE-UHFFFAOYSA-N Cc(c([N+]([O-])=O)c1)cc(F)c1C(O)=O Chemical compound Cc(c([N+]([O-])=O)c1)cc(F)c1C(O)=O UBAWHHHAAFFKGE-UHFFFAOYSA-N 0.000 description 1
- MBNOTYINXNBURZ-UHFFFAOYSA-N Cc(c([N+]([O-])=O)cc(Cl)c1)c1C(N1CCN(C)CC1)=O Chemical compound Cc(c([N+]([O-])=O)cc(Cl)c1)c1C(N1CCN(C)CC1)=O MBNOTYINXNBURZ-UHFFFAOYSA-N 0.000 description 1
- WLWGJMFTWWHOOR-UHFFFAOYSA-N Cc(cc(C1CN(C)CCC1)c(C#N)c1)c1N Chemical compound Cc(cc(C1CN(C)CCC1)c(C#N)c1)c1N WLWGJMFTWWHOOR-UHFFFAOYSA-N 0.000 description 1
- WRXKWGJLBYHGKE-UHFFFAOYSA-N Cc1cc(F)c(CO)cc1[N+]([O-])=O Chemical compound Cc1cc(F)c(CO)cc1[N+]([O-])=O WRXKWGJLBYHGKE-UHFFFAOYSA-N 0.000 description 1
- MPYNYOFTORDKNG-UHFFFAOYSA-N Cc1cc([N+]([O-])=O)c(CN2CCOCC2)cc1 Chemical compound Cc1cc([N+]([O-])=O)c(CN2CCOCC2)cc1 MPYNYOFTORDKNG-UHFFFAOYSA-N 0.000 description 1
- BFELLSYKJYHQOF-UHFFFAOYSA-N N#Cc1cc([N+]([O-])=O)c(CN2CCOCC2)cc1 Chemical compound N#Cc1cc([N+]([O-])=O)c(CN2CCOCC2)cc1 BFELLSYKJYHQOF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152416.0 | 2016-01-22 | ||
| EP16152416 | 2016-01-22 | ||
| EP16159651.5 | 2016-03-10 | ||
| EP16159651 | 2016-03-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201728577A TW201728577A (zh) | 2017-08-16 |
| TWI739783B true TWI739783B (zh) | 2021-09-21 |
Family
ID=57868252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105143703A TWI739783B (zh) | 2016-01-22 | 2017-01-20 | 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11180487B2 (enExample) |
| EP (1) | EP3405196B1 (enExample) |
| JP (1) | JP6910359B2 (enExample) |
| KR (1) | KR102784966B1 (enExample) |
| CN (1) | CN108697710B (enExample) |
| AU (1) | AU2017209935B2 (enExample) |
| BR (1) | BR112018014675B1 (enExample) |
| CA (1) | CA3011880A1 (enExample) |
| DK (1) | DK3405196T3 (enExample) |
| ES (1) | ES2775449T3 (enExample) |
| HR (1) | HRP20200133T1 (enExample) |
| HU (1) | HUE047684T2 (enExample) |
| IL (1) | IL260500B (enExample) |
| LT (1) | LT3405196T (enExample) |
| MX (1) | MX2018008974A (enExample) |
| PH (1) | PH12018501567A1 (enExample) |
| SI (1) | SI3405196T1 (enExample) |
| TW (1) | TWI739783B (enExample) |
| WO (1) | WO2017125530A1 (enExample) |
| ZA (1) | ZA201804688B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| JP6740452B2 (ja) * | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
| MX2020003240A (es) * | 2017-09-30 | 2020-11-24 | Shanghai Haihe Pharmaceutical Co Ltd | Compuesto que tiene actividad inhibidora de la quinasa erk y su uso. |
| TW202045008A (zh) | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| CN111793031B (zh) * | 2019-04-02 | 2021-06-22 | 海创药业股份有限公司 | 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途 |
| MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4393508A4 (en) * | 2021-08-23 | 2024-12-04 | Osaka University | COMPOSITION FOR SUPPRESSING TRANSDIFFERENTIATION OF MATURE HEPATOCYTES |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| AU2001237041B9 (en) | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| ES2608670T3 (es) | 2009-08-17 | 2017-04-12 | Memorial Sloan-Kettering Cancer Center | Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| PT2598483T (pt) | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| CN103732067A (zh) * | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | 化合物，组合物及它们的治疗用途 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| CA2922657C (en) | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| EP3489232A3 (en) | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP2017520526A (ja) | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN106715419A (zh) | 2014-09-26 | 2017-05-24 | 吉利德科学公司 | 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物 |
| CN106928216A (zh) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
-
2017
- 2017-01-20 US US16/071,192 patent/US11180487B2/en active Active
- 2017-01-20 WO PCT/EP2017/051150 patent/WO2017125530A1/en not_active Ceased
- 2017-01-20 CN CN201780007786.1A patent/CN108697710B/zh active Active
- 2017-01-20 CA CA3011880A patent/CA3011880A1/en active Pending
- 2017-01-20 EP EP17701110.3A patent/EP3405196B1/en active Active
- 2017-01-20 HU HUE17701110A patent/HUE047684T2/hu unknown
- 2017-01-20 TW TW105143703A patent/TWI739783B/zh not_active IP Right Cessation
- 2017-01-20 BR BR112018014675-7A patent/BR112018014675B1/pt active IP Right Grant
- 2017-01-20 AU AU2017209935A patent/AU2017209935B2/en active Active
- 2017-01-20 ES ES17701110T patent/ES2775449T3/es active Active
- 2017-01-20 JP JP2018535876A patent/JP6910359B2/ja active Active
- 2017-01-20 KR KR1020187024257A patent/KR102784966B1/ko active Active
- 2017-01-20 SI SI201730183T patent/SI3405196T1/sl unknown
- 2017-01-20 HR HRP20200133TT patent/HRP20200133T1/hr unknown
- 2017-01-20 MX MX2018008974A patent/MX2018008974A/es unknown
- 2017-01-20 DK DK17701110.3T patent/DK3405196T3/da active
- 2017-01-20 LT LTEP17701110.3T patent/LT3405196T/lt unknown
-
2018
- 2018-07-09 IL IL260500A patent/IL260500B/en active IP Right Grant
- 2018-07-13 ZA ZA2018/04688A patent/ZA201804688B/en unknown
- 2018-07-23 PH PH12018501567A patent/PH12018501567A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3011880A1 (en) | 2017-07-27 |
| CN108697710B (zh) | 2022-02-18 |
| ZA201804688B (en) | 2022-03-30 |
| AU2017209935A1 (en) | 2018-08-09 |
| LT3405196T (lt) | 2020-02-25 |
| DK3405196T3 (en) | 2020-03-09 |
| BR112018014675A2 (pt) | 2018-12-11 |
| EP3405196B1 (en) | 2019-12-04 |
| CN108697710A (zh) | 2018-10-23 |
| KR20180100441A (ko) | 2018-09-10 |
| HUE047684T2 (hu) | 2020-05-28 |
| EP3405196A1 (en) | 2018-11-28 |
| ES2775449T3 (es) | 2020-07-27 |
| TW201728577A (zh) | 2017-08-16 |
| US20210087182A1 (en) | 2021-03-25 |
| PH12018501567A1 (en) | 2019-01-28 |
| SI3405196T1 (sl) | 2020-03-31 |
| US11180487B2 (en) | 2021-11-23 |
| JP2019504067A (ja) | 2019-02-14 |
| JP6910359B2 (ja) | 2021-07-28 |
| MX2018008974A (es) | 2018-11-09 |
| HRP20200133T1 (hr) | 2020-05-15 |
| IL260500B (en) | 2021-01-31 |
| AU2017209935B2 (en) | 2021-04-01 |
| BR112018014675B1 (pt) | 2023-12-19 |
| WO2017125530A1 (en) | 2017-07-27 |
| KR102784966B1 (ko) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI739783B (zh) | 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物 | |
| CN109641882B (zh) | 作为nik抑制剂的杂芳族衍生物 | |
| CN109311846B (zh) | 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物 | |
| CN109689645B (zh) | 作为nik抑制剂的氰基吲哚啉衍生物 | |
| CN107074881B (zh) | 作为nik抑制剂的新的噻吩并嘧啶衍生物 | |
| TW201602103A (zh) | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 | |
| CN107074882B (zh) | 作为nik抑制剂的新的吡唑并嘧啶衍生物 | |
| TW201602104A (zh) | 用作ＮＩＫ抑制劑之新的１－（４－嘧啶基）－１Ｈ－吡唑並［３，２－ｃ］吡啶衍生物 | |
| CN110831940B (zh) | 作为nik抑制剂的新取代的氮杂吲哚啉衍生物 | |
| WO2024083255A1 (zh) | 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途 | |
| RU2780577C2 (ru) | Новые замещенные производные азаиндолина в качестве ингибиторов nik | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |